Equities

Notable Labs Ltd

NTBL:NAQ

Notable Labs Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)0.68
  • Today's Change-0.21 / -23.60%
  • Shares traded186.86k
  • 1 Year change+166.67%
  • Beta1.0128
Data delayed at least 15 minutes, as of Jun 14 2024 21:00 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Notable Labs Ltd, formerly Vascular Biogenics Ltd, is an Israel-based clinical-stage biopharmaceutical company committed to developing next-generation, targeted medicines for difficult-to-treat medical conditions. The Company has created a pipeline of therapeutics that address cancer and immune-inflammatory diseases with the goal of significantly improving patient outcomes and overcoming the limitations of approved treatments. The Company's product candidates are built off of two platform technologies: Vascular Targeting System (VTS), a gene-based technology targeting newly formed blood vessels, and Monocyte Targeting Technology (MTT), an antibody-based technology able to specifically inhibit monocyte migration for immune-inflammatory applications.

  • Revenue in USD (TTM)311.00k
  • Net income in USD-12.39m
  • Incorporated2000
  • Employees16.00
  • Location
    Notable Labs Ltd320 Hatch DriveFOSTER CITY 94404United StatesUSA
  • Phone+1 (415) 851-2410
  • Fax+972 8993-5001
  • Websitehttps://notablelabs.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
AiXin Life International Inc4.09m-2.09m5.82m207.00------1.42-0.0836-0.08360.1636-0.07650.82685.4310.0219,757.49-42.27-16.93---34.5416.2548.13-51.12-36.960.1515------51.0058.0867.18--194.59--
eFFECTOR Therapeutics Inc0.00-34.63m5.88m14.00--5.90-----13.31-13.310.000.21190.00----0.00-141.18-----------------17.120.9581---100.00---58.00------
Xenetic Biosciences Inc2.44m-4.47m5.95m4.00--0.6854--2.43-2.92-2.921.595.630.2116----611,240.00-38.71-48.91-41.54-52.82-----182.95-682.42----0.00--48.80--36.90------
TFF Pharmaceuticals Inc885.71k-19.93m6.01m19.00--0.9214--6.79-10.20-10.200.43712.110.0647--3.7246,616.32-145.46-79.57-181.57-83.41-----2,249.83-8,687.66----0.00--48.01--33.13------
Hepion Pharmaceuticals Inc0.00-38.52m6.07m22.00--1.04-----9.49-9.490.001.370.00----0.00-117.64-61.43-145.05-68.82-----------3,240.310.00-------7.92------
Notable Labs Ltd311.00k-12.39m6.13m16.00--0.5312--19.72-2.31-2.310.06221.280.0142----19,437.50-56.70-52.02-74.10-62.0937.3060.19-3,984.24-3,636.93----0.0271---52.89-11.9365.13---50.69--
Tenax Therapeutics Inc0.00-10.10m6.15m5.00--0.4947-----24.52-24.520.006.350.00----0.00-67.96-199.16-75.66-285.64-----------105.120.0322------30.21------
Glucose Health Inc1.11m-456.46k6.19m2.00--6.53--5.56-0.033-0.0330.08030.0561-----------86.94---153.9547.1940.68-31.99-56.93313.11--0.00--98.3924.9416.87------
BioCardia Inc468.00k-10.34m6.21m16.00------13.26-7.04-7.040.3132-1.270.0954--4.4429,250.00-210.81-107.34-1,190.90-154.17-----2,208.76-1,779.24---------64.72-5.262.82---28.89--
GT Biopharma Inc0.00-9.64m6.23m2.00--0.7513-----7.04-7.040.003.850.00----0.00-64.24-205.36-90.39--------------0.00------63.62------
Kineta Inc5.16m-17.89m6.24m11.00------1.21-1.55-1.550.4673-0.5640.6667----469,181.80-230.51-66.16---86.61-----345.77-854.74--------178.6513.8977.76------
Sunshine Biopharma Inc26.74m-4.09m6.25m44.00--0.0132--0.2338-13.35-13.3576.9624.960.90813.1311.58607,722.50-13.88-101.52-17.99-137.0433.1535.47-15.29-165.333.23--0.00--454.42--83.15--110.99--
NuCana PLC (ADR)0.00-33.74m6.34m25.00--0.5312-----301.53-301.530.005.650.00----0.00-72.34-41.01-125.17-48.07------------0.0324------13.71---21.70--
Titan Pharmaceuticals Inc87.00k-4.95m6.34m4.00--1.04--72.93-6.41-6.410.11196.660.0197--1.2321,750.00-112.41-96.80-170.59-156.65-----5,694.25-406.26---415.190.00---66.97-51.1645.43---65.61--
Intelligent Bio Solutions Inc2.83m-10.03m6.42m17.00--0.5392--2.27-64.14-64.144.603.820.20412.697.77166,299.40-72.67-80.65-107.67-224.8423.33---356.09-948.541.87--0.0451--187.51367.97-28.00------
Data as of Jun 14 2024. Currency figures normalised to Notable Labs Ltd's reporting currency: US Dollar USD

Institutional shareholders

1.56%Per cent of shares held by top holders
HolderShares% Held
Squarepoint OPS LLCas of 31 Mar 202463.70k0.71%
Mariner LLCas of 31 Mar 202422.00k0.24%
Morgan Stanley & Co. LLCas of 31 Mar 202419.30k0.21%
Two Sigma Securities LLCas of 31 Mar 202414.44k0.16%
XTX Markets LLCas of 31 Mar 202410.19k0.11%
Wells Fargo Clearing Services LLCas of 31 Mar 20245.00k0.06%
UBS Securities LLCas of 31 Mar 20243.93k0.04%
Group One Trading LPas of 31 Mar 20241.27k0.01%
Securities America Advisors, Inc.as of 31 Mar 2024630.000.01%
Harel Mutual Funds Ltd.as of 31 Mar 2024314.000.00%
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.